IPO - Taysha Gene Therapies, Inc.

Form Type: 424B5

Filing Date: 2025-05-29

Corporate Action: Ipo

Type: New

Accession Number: 000119312525130693

Filing Summary: Taysha Gene Therapies, Inc. is offering 46,868,687 shares of common stock at a public offering price of $2.75 per share. Additionally, they are offering pre-funded warrants to purchase up to 25,858,586 shares of common stock, with the exercise price of each warrant being $0.001 less than the offering price. The document outlines the expected total proceeds to Taysha before expenses of approximately $187,974,142. The company intends to grant underwriters an option to purchase an additional 10,909,090 shares. The document indicates that Taysha is an 'emerging growth company' and registered under the SEC rules, subject to reduced reporting requirements. Risks associated with the investment are highlighted, and the share price is noted to be $2.605 as of May 27, 2025. The offering relates to a pivotal Part B clinical trial for TSHA-102 for Rett syndrome, with positive clinical data reported from prior trials. This is the first public announcement regarding the offering within the framework of their ongoing development program for gene therapies targeting severe conditions.

Form Type: 8-K

Filing Date: 2025-05-29

Corporate Action: Ipo

Type: New

Accession Number: 000119312525130709

Filing Summary: On May 28, 2025, Taysha Gene Therapies, Inc. entered into an underwriting agreement with several underwriters to issue and sell 46,868,687 shares of common stock and pre-funded warrants to purchase 25,858,586 shares. The offering price is set at $2.75 per share and $2.749 per pre-funded warrant. The underwriters are set to purchase the securities at $2.585 per share. Taysha expects net proceeds of approximately $187.4 million from the offering, and possibly $215.6 million if the underwriters purchase additional shares. The transaction closing is anticipated for May 30, 2025, with customary closing conditions. The company issued press releases announcing the launch and pricing of this offering on the same day. The proceeds will support the company's operating expenses into 2028.

Form Type: 424B5

Filing Date: 2025-05-28

Corporate Action: Ipo

Type: New

Accession Number: 000119312525129569

Filing Summary: Taysha Gene Therapies, Inc. filed a preliminary prospectus supplement on May 28, 2025, in connection with an IPO offering. The offering includes shares of common stock and pre-funded warrants to purchase common stock. The company is offering shares at an unspecified public offering price and has specified underwriting discounts and commissions. The clinical-stage biotechnology company focuses on AAV-based gene therapies, particularly TSHA-102 targeting Rett syndrome. Recent developments include a regulatory update regarding the pivotal Part B trial design for TSHA-102, following alignment with the FDA. Key data from ongoing REVEAL Phase 1/2 trials showed that all treated patients gained or regained developmental milestones, suggesting the potential effectiveness of TSHA-102. The offering is part of Taysha's effort to address significant unmet medical needs in severe monogenic diseases of the CNS, with an emphasis on advancing their lead clinical program in Rett syndrome. The last reported stock price prior to the offering was $2.605 per share, indicating a strategic move to raise capital for further development and commercialization of their therapies.